En vigtig lovændring kræver, at ansøgere inkludere en risikostyringsplan i deres ansøgning, som skal vurderes af Udvalget for Humanmedicinske Lægemidler (CHMP).
An important legislative change requires applicants to include an RMP in their application, to be evaluated by the Committee for Medicinal Products for Human Use (CHMP).